Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp's Esoterix and DHMRI Collaborate on Assay Development

NEW YORK (GenomeWeb News) – Laboratory Corporation of America division Esoterix Clinical Trial Services today announced a deal with the David H. Murdock Research Institute for assay development.

As part of the deal, assays developed at DHMRI will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides for the downstream commercialization of companion diagnostics and other biomarker assays upon clinical validation, Esoterix said.

The deal provides LabCorp's clinical trials clients "the most complete suite of biomarker development tools in the industry," David Johnston, senior vice president and global head of clinical trials for LabCorp, said in a statement.

Services available to LabCorp's clients through the DHMRI include biomarker discovery and proof-of-concept assay develop for early- and late-stage drug discovery and development.

Financial and other terms of the deal were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.